Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level ≤ 10 ng/ml: Radiation therapy or surgery?

International Journal of Radiation Oncology Biology Physics

Volumn 38, Issue 4, 1997, Pages 723-729

  Keyser, Douglas ^a   Kupelian, Patrick A ^a   Zippe, Craig D ^a   Levin, Howard S ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Prognostic factors; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGED; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0030758727     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00123-5     Document Type: Article

References (24)

1. 125iodine implantation for stage T1/T2 prostate carcinoma. J. Urol. 154:1096-1099; 1995.
2. Cox, D. Regression models and life-tables. J. Roy. Stat. Soc. 34:187; 1982.
3. D'Amico, A.; Whittington, R.; Malkowicz, S.; Schultz, D.; Schnall, M.; Tomaszewski, J.; Wein, A. A multivariate analysis of clinical and pathologic factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol. 154:131-138; 1995.
4. Epstein, J.; Pizov, G.; Walsh, P. Correlation of pathologic findings with progression following radical prostatectomy. Cancer 71:3582-3593; 1993.
5. Frazier, H.; Robertson, J.; Humphrey, P.; Paulson, D. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J. Urol. 149:516-518; 1993.
6. Harris, E.; Albert, A. Survivorship analysis for clinical studies. New York: Marcel Dekker; 1991.
7. Kaplan, I.; Cox, R.; Bagshaw, M. Prostate specific antigen after external beam radiotherapy for prostate cancer: Follow-up. J. Urol. 149:519-522; 1993.
8. Kuban, D.; El-Mahdi, A.; Schellhammer, P. Pretreatment PSA as a predictor of long-term outcome in patients definitely irradiated for prostatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 30(Suppl 1):156-157; 1994.
9. Kupelian, P.; Katcher, J.; Levin, H.; Zippe, C.; Klein, E. Correlation of clinical and pathologic factors with rising PSA profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48:249-260; 1996.
10. Kupelian, P.; Levin, H.; Zippe, C.; Klein, E. External beam radiotherapy vs. radical prostatectomy for localized prostate cancer: A single institution experience. J. Urol. 155:556A; 1996.
11. Oesterling, J. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145:907-923; 1991.
12. Partin, A.; Pound, C.; Clemens, J.; Epstein, J.; Walsh, P. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. North. Am. 20:713-725; 1993.
13. Paulson, D.; Lin, G.; Hinshaw, W.; Stephani, S. Radical surgery vs. radiotherapy for adenocarcinoma of the prostate. J. Urol. 128:502-504; 1982.
14. Pilepich, M.; Krall, J.; Al-Sarraf, M.; John, M.; Doggett, S.; Sause, W.; Lawton, C.; Abrams, R.; Rotman, M.; Rubin, P.; Shipley, W.; Grignon, D.; Caplan, R.; Cox, J. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the RTOG. Urology 45:616-623; 1995.
15. Ritter, M.; Messing, E.; Shanahan, T.; Potts, S.; Chappell, R.; Kinsella, T. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1208-1217; 1992.
16. Sandler, H.; McLaughlin, W.; Kish, K.; Lichter, A. Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32(Suppl 1):141; 1995.
17. Schellhammer, P.; El-Mahdi, A.; Wright, G.; Kolm, P.; Ragle, R. Prostatic-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology 42:13-20; 1993.
18. Stamey, T.; Ferrari, M.; Schmid, H. The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J. Urol. 150:1856-1859; 1993.
19. Stein, A.; deKernion, J.; Smith, R.; Dorey, F.; Patel, H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J. Urol. 147:942-946; 1992.
20. Trapasso, J.; deKernion, J.; Smith, R.; Dorey, F. The incidence and significance of detectable levels of serum prostate-specific antigen after radical prostatectomy. J. Urol. 152: 1821; 1994.
21. Zagars, G.; Pollack, A. Radiation Therapy for T1 and T2 prostate cancer: Prostatic-specific antigen and disease outcome. Urology 45:476-483; 1995.
22. Zagars, G.; von Eschenbach, A. Prognostic factors in prostate cancer: Prostate specific antigen: An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72:538-548; 1993.
23. Zelefsky, M.; Leibel, S.; Wallner, K.; Whitmore, W.; Fuks, Z. Significance of normal serum prostate specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J. Clin. Oncol. 13:459-463; 1995.
24. Zietman, A.; Coen, J.; Shipley, W.; Willett, C.; Efrid, J. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate-specific antigen value as a predictor of treatment outcome. J. Urol. 151:640-645; 1994.